• +1-646-491-9876
    • +91-20-67278686

    Search

    Influenzavirus B Infections - Pipeline Review, H1 2017

    Influenzavirus B Infections - Pipeline Review, H1 2017

    • Report Code ID: RW0001709447
    • Category Pharmaceuticals
    • No. of Pages 111
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Influenzavirus B Infections - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Influenzavirus B Infections - Pipeline Review, H1 2017, provides an overview of the Influenzavirus B Infections (Infectious Disease) pipeline landscape.

    Type B influenza is a subtype of the influenza virus that tends to occur sporadically. Symptoms include runny nose, sore throat, aching muscles, malaise, watery eyes, aching body, loss of appetite and weakness. Treatment includes antiviral, analgesics and antipyretics medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Influenzavirus B Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Influenzavirus B Infections (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Influenzavirus B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenzavirus B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 13, 3, 2, 7 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Discovery stages comprises 1, 1, 1 and 2 molecules, respectively.

    Influenzavirus B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Influenzavirus B Infections (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Influenzavirus B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Influenzavirus B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Influenzavirus B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Influenzavirus B Infections (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Influenzavirus B Infections (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Influenzavirus B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Influenzavirus B Infections - Overview
    Influenzavirus B Infections - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Influenzavirus B Infections - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Influenzavirus B Infections - Companies Involved in Therapeutics Development
    AbbVie Inc
    Altravax Inc
    Amarillo Biosciences Inc
    Aphios Corp
    BioClonetics Immunotherapeutics Inc
    ContraFect Corp
    Daiichi Sankyo Company Ltd
    GlaxoSmithKline Plc
    Green Cross Corp
    Ilyang Pharmaceutical Co Ltd
    Kineta Inc
    Medicago Inc
    MedImmune LLC
    Mucosis BV
    Novavax Inc
    Protein Sciences Corp
    Romark Laboratories LC
    Sanofi Pasteur SA
    Shionogi & Co Ltd
    SK Chemicals Co Ltd
    Toyama Chemical Co Ltd
    TSRL Inc
    Vaxart Inc
    Vectura Group Plc
    Zydus Cadila Healthcare Ltd
    Influenzavirus B Infections - Drug Profiles
    AL-18 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APP-0205 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APP-309 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CF-403 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CF-404 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    favipiravir - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Fluad (quadrivalent) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FluGEM - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GC-3106A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza (split virion, tetravalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [serotype B] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [serotypes A, B] (virus like particle) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B/victoria+ B/yamagata] (quadrivalent, split virion) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    influenza [strains A/H1N1 + A/H3N2 + B] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    interferon alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KIN-1400 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    laninamivir - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza A and B Virus Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody for Influenza B Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody for Influenza B Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NBP-607 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nitazoxanide CR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S-033188 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VR-736 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VXABYW-10 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    zanamivir - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    zanamivir - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Influenzavirus B Infections - Dormant Projects
    Influenzavirus B Infections - Discontinued Products
    Influenzavirus B Infections - Product Development Milestones
    Featured News & Press Releases
    Mar 06, 2017: TSRL Awarded NIH Grant to Develop Microneedle Patch for Treatment of Influenza
    Dec 01, 2016: Secondary Endpoint Data for S-033188, a Novel Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, Support Favorable Primary Endpoint Data Previously Released
    Aug 29, 2016: Seqirus receives FDA approval for AFLURIA QUADRIVALENT (Influenza Vaccine) for people 18 years of age and older
    Aug 29, 2016: Shionogi Presents Results from a Phase 2 Proof-of-Concept Clinical Trial and Non-Clinical Studies of S-033188, a Novel Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza
    Aug 26, 2016: Daiichi Sankyo Receives Additional Dosage Regimen Approval in Japan for Long-acting Neuraminidase Inhibitor Inavir Dry Powder Inhaler 20mg
    Aug 25, 2016: VALNEVA Announces Signing of Marketing & Distribution Agreement for Seqirus' Flu vaccine Fluad in Austria
    Jun 23, 2016: New Four-Strain Influenza Vaccine, VaxigripTetra, regulatory dossier from Sanofi Pasteur now approved in Europe
    Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season
    Feb 12, 2016: Protein Sciences and UNIGEN Reach Agreement to Source Flublok Influenza Vaccine from Japan
    Dec 17, 2015: Vaxart Announces Enrollment of First Patient in Influenza B Phase 1 Trial
    Jun 04, 2015: Kineta's Novel Broad Spectrum Antivirals Trigger Effective Natural Immune Response to Flu and Respiratory Virus Infections
    May 12, 2015: Kineta Presents Data On Novel Antiviral Compounds Which Inhibit Broad Spectrum of Respiratory Diseases At International Antiviral Conference
    Aug 01, 2014: Biota Reports Top-Line Data From Its Phase 2 "IGLOO" Trial of Laninamivir Octanoate
    May 08, 2014: Biota Provides Update on BARDA Contract for Laninamivir Octanoate
    Dec 20, 2013: Biota Reports That Laninamivir Octanoate is Approved for the Prevention of Influenza in Japan
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Influenzavirus B Infections, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Influenzavirus B Infections - Pipeline by AbbVie Inc, H1 2017
    Influenzavirus B Infections - Pipeline by Altravax Inc, H1 2017
    Influenzavirus B Infections - Pipeline by Amarillo Biosciences Inc, H1 2017
    Influenzavirus B Infections - Pipeline by Aphios Corp, H1 2017
    Influenzavirus B Infections - Pipeline by BioClonetics Immunotherapeutics Inc, H1 2017
    Influenzavirus B Infections - Pipeline by ContraFect Corp, H1 2017
    Influenzavirus B Infections - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Influenzavirus B Infections - Pipeline by GlaxoSmithKline Plc, H1 2017
    Influenzavirus B Infections - Pipeline by Green Cross Corp, H1 2017
    Influenzavirus B Infections - Pipeline by Ilyang Pharmaceutical Co Ltd, H1 2017
    Influenzavirus B Infections - Pipeline by Kineta Inc, H1 2017
    Influenzavirus B Infections - Pipeline by Medicago Inc, H1 2017
    Influenzavirus B Infections - Pipeline by MedImmune LLC, H1 2017
    Influenzavirus B Infections - Pipeline by Mucosis BV, H1 2017
    Influenzavirus B Infections - Pipeline by Novavax Inc, H1 2017
    Influenzavirus B Infections - Pipeline by Protein Sciences Corp, H1 2017
    Influenzavirus B Infections - Pipeline by Romark Laboratories LC, H1 2017
    Influenzavirus B Infections - Pipeline by Sanofi Pasteur SA, H1 2017
    Influenzavirus B Infections - Pipeline by Shionogi & Co Ltd, H1 2017
    Influenzavirus B Infections - Pipeline by SK Chemicals Co Ltd, H1 2017
    Influenzavirus B Infections - Pipeline by Toyama Chemical Co Ltd, H1 2017
    Influenzavirus B Infections - Pipeline by TSRL Inc, H1 2017
    Influenzavirus B Infections - Pipeline by Vaxart Inc, H1 2017
    Influenzavirus B Infections - Pipeline by Vectura Group Plc, H1 2017
    Influenzavirus B Infections - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
    Influenzavirus B Infections - Dormant Projects, H1 2017
    Influenzavirus B Infections - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Influenzavirus B Infections, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AbbVie Inc
    Altravax Inc
    Amarillo Biosciences Inc
    Aphios Corp
    BioClonetics Immunotherapeutics Inc
    ContraFect Corp
    Daiichi Sankyo Company Ltd
    GlaxoSmithKline Plc
    Green Cross Corp
    Ilyang Pharmaceutical Co Ltd
    Kineta Inc
    Medicago Inc
    MedImmune LLC
    Mucosis BV
    Novavax Inc
    Protein Sciences Corp
    Romark Laboratories LC
    Sanofi Pasteur SA
    Shionogi & Co Ltd
    SK Chemicals Co Ltd
    Toyama Chemical Co Ltd
    TSRL Inc
    Vaxart Inc
    Vectura Group Plc
    Zydus Cadila Healthcare Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//influenzavirus-b-infections-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//influenzavirus-b-infections-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//influenzavirus-b-infections-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments